Literature DB >> 20370618

Viral infection and cancer: the NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes.

Stavroula Baritaki1, Benjamin Bonavida.   

Abstract

The anti-viral/tumor cytotoxic T cells exert their killing mechanisms by the granzyme-perforin and death ligand-induced necrosis and apoptosis. These death ligands include TNF-alpha (tumor-necrosis factor-alpha), FasL (Fas ligand), and TRAIL (TNF-related apoptosis-inducing ligand). However, many target cells resist killing by the cytotoxic T cells. Tis review discusses potential novel underlying mechanisms of resistance and implicate an NF-kappaB (nuclear factor kappa beta)-Snail (SNAI-1)-RKIP (Raf-1 kinase inhibitor protein) circuitry in resistant targets. TRAIL-mediated killing of a tumor cell line is used as an example to illustrate the circuitry. Tumor cells resistant to TRAIL-mediated apoptosis can be sensitized by NF-kappaB inhibitors. Inhibition of NF-kappaB results in the induction of RKIP. RKIP overexpression sensitizes the cells to TRAIL. RKIP is induced following inhibition of the RKIP transcription repressor, Snail, downstream of NF-kappaB. Snail siRNA reverses resistance to TRAIL. Because RKIP negatively regulates NF-kappaB, we propose that the resistant cell phenotype could be maintained through Snail-mediated RKIP suppression which supports the constitutive NF-kappaB activation. This review introduces a new paradigm, namely, that the cytotoxic T-cell response to viral infection and/or cancer may be compromised by the target cells expressing the resistant NF-kappaB-Snail-RKIP phenotype. Alternative therapeutic interventions, such as various inhibitors, NF-kappaB inhibitors, and siRNAs, are presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370618     DOI: 10.1615/critrevimmunol.v30.i1.20

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  13 in total

1.  Prognostic value of raf kinase inhibitor protein in esophageal squamous cell carcinoma.

Authors:  Chengcheng Gao; Liqun Pang; Chengcheng Ren; Tianheng Ma
Journal:  Pathol Oncol Res       Date:  2011-11-19       Impact factor: 3.201

2.  Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells.

Authors:  Tun-Chieh Chen; Ya-Ling Hsu; Yu-Chieh Tsai; Yu-Wei Chang; Po-Lin Kuo; Yen-Hsu Chen
Journal:  J Mol Med (Berl)       Date:  2013-09-05       Impact factor: 4.599

3.  Systemic TNFα gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer.

Authors:  Baowei Su; Arzu Cengizeroglu; Katarina Farkasova; Joana R Viola; Martina Anton; Joachim W Ellwart; Rudolf Haase; Ernst Wagner; Manfred Ogris
Journal:  Mol Ther       Date:  2012-11-13       Impact factor: 11.454

4.  The complex interplay between autophagy and NF-κB signaling pathways in cancer cells.

Authors:  Aurore Trocoli; Mojgan Djavaheri-Mergny
Journal:  Am J Cancer Res       Date:  2011-04-26       Impact factor: 6.166

5.  Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.

Authors:  Si Wei Li; Hua Wang; Mei Lian Liu; Hai Bo Zhang; Yan Qun Xiang; Xing Lv; Wei Xiong Xia; Mu Sheng Zeng; Hai Qiang Mai; Ming Huang Hong; Xiang Guo
Journal:  Med Oncol       Date:  2012-12-15       Impact factor: 3.064

6.  A new model for raf kinase inhibitory protein induced chemotherapeutic resistance.

Authors:  Fahd Al-Mulla; Milad S Bitar; Jingwei Feng; Sungdae Park; Kam C Yeung
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

7.  Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas.

Authors:  Olga Martinho; Sara Granja; Teresa Jaraquemada; Cláudia Caeiro; Vera Miranda-Gonçalves; Mrinalini Honavar; Paulo Costa; Margarida Damasceno; Marsha R Rosner; José M Lopes; Rui M Reis
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

8.  A New Paradigm to Mitigate Osteosarcoma by Regulation of MicroRNAs and Suppression of the NF-κB Signaling Cascade.

Authors:  Raj Kumar Mongre; Simrinder Singh Sodhi; Mrinmoy Ghosh; Jeong Hyun Kim; Nameun Kim; Neelesh Sharma; Dong Kee Jeong
Journal:  Dev Reprod       Date:  2014-12

9.  RKIP reduction enhances radioresistance by activating the Shh signaling pathway in non-small-cell lung cancer.

Authors:  Shi-Yang Xie; Guang Li; Chong Han; Yang-Yang Yu; Nan Li
Journal:  Onco Targets Ther       Date:  2017-11-23       Impact factor: 4.147

Review 10.  Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma.

Authors:  Anna Shvartsur; Kevin B Givechian; Hermes Garban; Benjamin Bonavida
Journal:  J Exp Clin Cancer Res       Date:  2017-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.